Want to see BBOT full AI Analyst Report?
BBOT Stock Chart & Stats
$9.37
--
Market closed
$9.37
--
Day’s Range― - ―
52-Week Range$3.48 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)630.99K
Market Cap
$288.63M
Enterprise Value-$222.59M
Total Cash (Recent Filing)$225.71M
Total Debt (Recent Filing)$2.51M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Nov 18, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1232.82
Shares Outstanding80,174,270
10 Day Avg. Volume629,819
30 Day Avg. Volume630,991
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap-0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.20K
Enterprise Value/Ebitda1.14
Forecast
1Y Price Target
$21.00Price Target Upside124.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low DebtVery low leverage limits interest obligations and reduces reliance on debt markets while BBOT funds oncology research. This gives management greater financing flexibility than a similarly loss-making biotech carrying substantial borrowings, although equity financing remains important.
Strengthened CapitalizationThe return to positive and substantial equity indicates that prior capital raises materially strengthened BBOT’s capitalization. A larger equity base can support continued development investment and provide a more durable financial cushion than the company had in earlier years.
Focused Oncology R&D ModelA focused oncology therapeutics development model aligns the company’s resources around a defined area of significant medical need. If its research programs progress successfully, this specialization could support differentiated clinical assets and future commercial opportunities.
Bears Say
Pre-Revenue StatusWith no revenue, BBOT has no operating sales base to offset research and development spending or fund operations internally. The company therefore remains dependent on clinical progress and future financing until a product can generate commercial revenue.
Widening Net LossesThe sharp expansion in net losses shows that BBOT’s current development model is consuming substantially more capital over time without revenue support. Persistently worsening earnings reduce the capital base and increase the resources required to reach future milestones.
Escalating Cash BurnDeeply negative and worsening operating and free cash flow means reported losses are translating into substantial real cash outflows. The burn rate creates ongoing dependence on external financing, with potential dilution risk as BBOT funds its development programs.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $3.48 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $288.63M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
BridgeBio Oncology Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 42 days.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
BridgeBio Oncology Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.705 earnings per share for the quarter, missing the consensus estimate of -$0.565 by -$0.14.
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,174,270 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
BridgeBio Oncology Therapeutics reported an EPS of -$0.705 in its last earnings report, missing expectations of -$0.565. Following the earnings report the stock price went up 2.391%.
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (124.12% Upside)
$21.00 (124.12% Upside)
Blogger Sentiment
Bullish
BBOT Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 355.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
90.84%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BBOT Stock 12 Month Forecast
Average Price Target
$21.00
▲(124.12% Upside)
Technical Analysis
Puma Biotechnology
―
CytomX Therapeutics
―
Kura Oncology
―
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Ownership Overview
40.70% Insiders
3.36% Mutual Funds
7.65% Other Institutional Investors
43.89% Public Companies and
Individual Investors